SCHEDULE 13G/A: Investment Funds Disclose 4.9% Stake in Annovis Bio, Inc. via Warrants

CVI Investments, Inc. and Heights Capital Management, Inc. have jointly disclosed a 4.9% beneficial ownership stake in Annovis Bio, Inc., primarily through warrants, as detailed in an amended Schedule 13G filing.

Summary

• CVI Investments, Inc. and Heights Capital Management, Inc. (collectively, the "Reporting Persons") have filed an amended Schedule 13G regarding their beneficial ownership in Annovis Bio, Inc.
• The Reporting Persons collectively beneficially own 1,000,000 shares of Annovis Bio, Inc. common stock.
• This ownership represents 4.9% of the company's outstanding common stock.
• The beneficially owned shares consist of shares issuable upon the exercise of warrants to purchase common stock.
• The warrants are not exercisable to the extent that the total beneficial ownership of a Reporting Person and its affiliates would exceed 4.99% of the outstanding shares.
• Heights Capital Management, Inc. serves as the investment manager to CVI Investments, Inc. and exercises shared voting and dispositive power over the reported shares.
• As of March 18, 2025, Annovis Bio, Inc. had 19,486,231 shares of common stock outstanding, according to their Annual Report on Form 10-K.
• The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The document is a routine regulatory filing disclosing a passive ownership stake. The presence of an institutional investor holding warrants can be interpreted as a vote of confidence, albeit without intent to influence control.

Positives

• The presence of an institutional investor like CVI Investments, Inc., managed by Heights Capital Management, Inc., holding a significant stake, even if passive, can be viewed as a vote of confidence in Annovis Bio, Inc.'s long-term prospects.
• The ownership is structured to remain below the 5% threshold, indicating a passive investment intent and avoiding more stringent reporting requirements, which can be seen as a stable, non-interfering investment.

Negatives

• The ownership being primarily through warrants introduces a potential for future dilution if these warrants are exercised, although the 4.99% beneficial ownership cap limits the immediate impact of such dilution.

Risks

• Potential future dilution of existing shareholders if the warrants held by the Reporting Persons are exercised, although this is capped at a 4.99% beneficial ownership level.
• The investment is explicitly stated as passive, meaning the Reporting Persons do not intend to influence control, which might limit their active engagement in corporate governance or strategic direction.

Future Outlook

The document is a beneficial ownership filing and does not contain forward-looking statements or guidance regarding the issuer's future performance, strategic outlook, or operational plans. It primarily details the current ownership structure of the Reporting Persons.

Management Comments

• The filing includes a certification from the Reporting Persons stating that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing is a routine disclosure of a passive investment stake in Annovis Bio, Inc., a company operating in the biotechnology sector. Such investments by institutional funds are common and reflect portfolio allocation decisions rather than specific industry-wide trends, though the holding suggests an interest in the pharmaceutical or neurological disease treatment sector where Annovis Bio, Inc. operates.

Comparison to Industry Standards

• This Schedule 13G filing is a standard regulatory disclosure for investors acquiring a significant, but non-controlling, stake in a public company, consistent with SEC regulations.
• The 4.9% ownership level is typical for passive institutional investments aiming to stay below the 5% threshold that triggers more extensive reporting requirements (Schedule 13D) and potential 'group' considerations, which is a common strategy among investment funds.
• There are no specific comparable companies, projects, or financial results mentioned in this filing to assess the results against global benchmarks, as the document focuses solely on beneficial ownership disclosure rather than operational or financial performance.

Stakeholder Impact

• Shareholders: The presence of an institutional investor holding a significant stake, even if passive, could be viewed positively as a sign of external validation. However, the nature of the ownership via warrants implies potential future dilution if exercised.
• Company Management: Awareness of a significant passive investor holding warrants, which may influence strategic considerations regarding capital structure and investor relations.

Next Steps

• The document does not specify any future actions, events, or milestones for Annovis Bio, Inc. or the Reporting Persons beyond the ongoing passive investment.

Key Dates

Keywords

Annovis Bio Inc., CVI Investments Inc., Heights Capital Management Inc., Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Investment Management, SEC Filing, Biotechnology, Pharmaceuticals